Podcasts about moffitt cancer center

Today we have Dr. Dominic D'Agostino, who over the past 10 years has been a frequent guest on STEM-Talk. Today Dom joins us to give us an update on his recent research into ketogenic metabolic therapies, ketone supplements as well as hyperbaric oxygen therapy for traumatic brain injuries. Dom and his lab at the University of South Florida have published more than 20 papers since his last appearance on STEM-Talk in 2023. Dom is an Associate Professor in the Department of Molecular Pharmacology and Physiology at South Florida's Morsani College of Medicine. Dom has a background in neuroscience, molecular pharmacology, nutrition and physiology. In addition to developing and testing metabolic-based therapies, Dom's lab also investigates seizure disorders, brain cancer, neurodegenerative diseases and rare genetic-metabolic disorders. Show notes: [00:03:28] Dawn welcomes Dom back to the show and explaining that he has been quite busy since his last appearance, authoring or co-authoring more than 20 papers. Over the past several years, Dom has been helping to advance the science and application of ketogenic metabolic therapy (KMT) with colleagues at Moffitt Cancer Center, particularly focusing on using KMT to enhance immune-based therapies for certain types of cancers. Dawn asks Dom about this collaboration. [00:05:04] Dawn explains that ketogenic metabolic therapy is a dietary approach that focuses on a high-fat/low-carb diet to reduce glucose availability for cancer cells, potentially slowing their growth and improving treatment outcomes. It has been explored as a complimentary treatment for a variety of cancers including gliomas by shifting the metabolism of tumor cells away from glucose. Dawn asks Dom to explain what is involved in KMT. [00:06:58] Dawn clarifies that KMT requires less than 20-25 grams of carbohydrates per day, and that ketosis is a metabolic state in which the body switches from glucose metabolism to metabolizing fats in the form of ketones. Dawn goes on to explain that cancer cells typically consume glucose at a higher rate than normal cells. However, cancer cells are also very adaptable, and Dawn asks Dom to talk about this feature of cancer cells. [00:09:14] Ken explains that KMT has shown the most promise in treating high-grade gliomas, or brain cancers, such as glioblastoma, which is the most aggressive primary brain tumor in adults. Ken explains that Dom was part of a massive review titled “Clinical research framework proposal for ketogenic metabolic therapy in glioblastoma,” which proposed guidelines for the management of glioblastoma based on an understanding of cancer as a metabolic disease, particularly involving mitochondria. Ken asks Dom to talk about this review. [00:11:21] From a patient advocacy perspective, Ken notes that the review recommends that there should be an aggressive education campaign that can arm patients with knowledge about KMT and other novel therapies. Ken asks Dom to talk about that recommendation. [00:13:15] Ken asks about the process of cutting the review from upwards of 200 pages down to around 50 pages with 49 authors. [00:15:04] Dawn mentions that Dom was part of another paper in 2024 titled “Targeting the mitochondrial stem cell connection in cancer treatment – a hybrid orthomolecular protocol.” Dawn explains that this paper looked at the mitochondrial stem cell connection theory (MSCC), which argues that cancer originates from chronic oxidative phosphorylation insufficiency in stem cells. This insufficiency leads to the formation of cancer stem cells and abnormal energy metabolism ultimately resulting in malignancy. There were 16 research centers and organizations involved in this paper which introduced a hybrid orthomolecular protocol to target the mitochondrial stem-cell connection. Dawn asks Dom to give an overview of MSCC. [00:18:26] Dawn explains that in this paper Dom and his co-authors propose a protocol that would enhance oxidative phosphorylation and inhibit the primary fuels of cancer, glucose and glutamine. This would target both cancer stem cells and metastasis. Dawn asks Dom to explain why this concept is attracting so much interest as a potential therapeutic approach for cancer. [00:20:48] Dawn asks if Dom could discuss the orthomolecular protocol, which is an approach that focuses on preventing and treating diseases by correcting nutritional balances in the body. [00:24:41] Ken asks if the proposed dietary intervention in the orthomolecular approach is different from a standard or typical ketogenic diet. [00:26:48] Ken shifts the discussion to talk about ketone supplements, explaining that Dom recently published a paper titled “Divergent hepatic outcomes of chronic ketone supplementation.” Ken goes on to explain that ketone salts preserve liver health, while some ketone esters and precursors appear to drive inflammation and steatosis. There is a lot of interest in ketone supplementation because they substantially elevate circulating ketones without having to restrict carbohydrates as strictly. The problem, as Ken explains, is that the long-term hepatic safety of ketone supplements remains unclear. In the aforementioned paper, Dom's rodent study evaluated the formulation-dependent impact of chronic ketone supplementation on liver histopathology, inflammatory signaling and systemic biomarkers. Ken asks Dom to discuss this paper and its findings and to give an overview of the various ketone supplements currently available. [00:30:49] Dawn asks Dom to dive into the methods and findings of the rodent study. [00:34:36] Ken asks Dom what his confidence is in the rodent model used in this study, and what are the next step for further research. [00:37:47] Regarding the two different doses given to rats in the study, Ken asks Dom how these doses correlate to doses in humans [00:40:23] Ken mentions that Ben Bikman, who was our guest on episode 143, published a study in February which Dom helped co-author. It examined the effects of ketone supplements on liver function. Ken asks Dom to discuss this study. [00:44:38] Dawn pivots to ask about a joint paper that Dom did with Andrew Koutnik, who was our guest on episode 185, on carbohydrates and physical performance titled “Carbohydrate ingestion on exercise metabolism and physical performance.” Dawn asks Dom to talk about this paper, which showed that a small amount of carbohydrates is sufficient to fuel athletic performance, and how additional carbohydrate intake showed diminishing returns. [00:49:18] Ken follows up on the finding that endurance athletes who rely on carb loading can tend toward pre-diabetes. [00:51:39] Ken asks Dom about the University of South Florida trial that Dom is an advisor for on traumatic brain injury and hyperbaric oxygen therapy. [00:54:41] Dawn mentions that Dom recently had an editorial in Frontiers that gave an overview of the emerging applications of hyperbaric/hyperbaric-oxygen therapy in the treatment of different neurological disorders. Dawn asks Dom what the key points in that editorial were. [00:59:06] Dawn explains that Dom recently gave a lecture at IHMC (available to view on IHMC's YouTube page), on traumatic brain injury and the populations at greatest risk in that context. Dawn asks Dom to give an overview of how an injury to the brain can result in neurometabolic crisis. [01:02:53] Ken asks Dom, excluding occupation demographics, what demographic is most at risk for traumatic brain injury (TBI) and why. [01:04:45] Ken mentions that it is understandable the risk that young people face with TBI due to the activities that young people engage in. Older people, however, have increased risk of TBI from falling as well as an additional age-related biological component that young people are not subject to. Ken asks Dom to elaborate on this. [01:07:12] Dawn mentions that several years ago, Dom and his wife bought some acreage in the countryside and started farming and asks Dom how the farm life is going. [01:07:57] Dawn closes the interview asking how Dom's wife is doing.

Dr. Yanina Pasikhova, Infectious Diseases Pharmacist at Moffitt Cancer Center and Research Institute, presents a talk on three lesser well known adverse drug effects involving antimicrobials. Dr. Pasikhova discusses the link between voriconazole and bone pain, the association between posaconazole and refractory hypertension and hypokalemia, and the neurological effects of of metronidazole therapy. Clinical pearls are provided for each interaction discussed.

In this episode, Lynn Ansley, Vice President of Revenue Cycle Management at Moffitt Cancer Center, joins the podcast to discuss how her team is leveraging automation, process optimization, and Epic implementation to transform revenue cycle operations.Learn more about relentlessly raising RCM yield here: https://med-metrix.com/?utm_source=beckers&utm_medium=podcast&utm_campaign=brand

Season 10, Episode 14: Optimizing Access Through OOLD In this episode of the PQI Podcast, we explore Oncology Optimized Limited Distribution (OOLD) and its growing importance within patient-centered oncology care. Guests Jonas Congelli, RPh, and Ken Komorny, PharmD, BCPS, discuss how distribution models impact oncology practices, care coordination, and the patient experience, while highlighting the critical role of medically integrated pharmacy services in supporting timely therapy initiation, education, adherence, and adverse event management. Jonas shares the vision behind OOLD and how medically integrated oncology teams help streamline care for patients receiving oral anticancer therapies. Ken provides insight into Moffitt Cancer Center's experience navigating operational, financial, and policy challenges related to specialty pharmacy access, including advocacy efforts. The conversation also highlights how oncology practices, manufacturers, and advocacy organizations can work together to preserve coordinated care models that prioritize patient safety, communication, and continuity of care. Throughout the episode, the discussion reinforces the value of multidisciplinary collaboration and innovation in shaping the future of oncology pharmacy practice and improving outcomes for patients nationwide. Learn more about NCODA and NCODA's OOLD initiatives here.View the poster Ken discussed here.

Today, Peggy talks with Daniel Gaylor, LCSW, OSW-C, ACHP-SW, and a social work supervisor at Moffitt Cancer Center, about what happens after patients and caregivers get through the intense treatment period and begin asking, “Now what?” Daniel explains that recovery does not mean life snaps back to normal. Survivorship brings fear, relief, hope, uncertainty, and exhaustion all at once. Those reactions are normal, and they deserve to be named. Daniel explains why post-traumatic stress disorder (PTSD) can show up after transplant. A transplant is not a routine treatment. It can involve long hospital stays, isolation, major physical side effects, and real fears about survival. When patients return for follow up visits, they may be brought back emotionally to those difficult hospital days. This can make survivorship feel complicated, even when the transplant was successful. Another key theme is slowly letting go. Patients may feel afraid to go out, socialize, eat in a restaurant, drive, or return to activities they once enjoyed. Daniel encourages survivors to start small and to be fair to the situation. It is easy to imagine the worst case. But it also helps to keep yourself honest - say out loud what could happen if things go well. The episode also addresses the “strain of worry.” Daniel describes signs of anxiety and depression, including sleep problems, racing thoughts, trouble concentrating, irritability, sadness, appetite changes, and not wanting to do things that usually bring joy. He reminds listeners that difficult days do not mean failure. Survivors should be able to say, “Today is not my best day,” and ask for help. Peggy and Daniel also talk about toxic positivity. While loved ones often mean well, phrases like “you're lucky to be alive” can minimize a survivor's fear or pain. Daniel encourages honest communication. Patients can thank loved ones for their support while also explaining what would help more. Social connection is another major part of healing. Daniel urges survivors and caregivers to increase connection and reduce isolation. A quick text, a short call, a support group, or a shared conversation can make a real difference. Peggy highlights programs where survivors can meet others who understand graft versus host disease (GVHD) and transplant recovery. Daniel closes with the idea of building a “tool belt.” Each person needs practical coping tools, whether that is a friend, music, journaling, counseling, mindfulness, a book, or a favorite place to reset. Caregivers need their own tool belts too. Transplant affects the whole support system, and survivorship works best when people communicate, ask for help, and remember they are not meant to do this alone. Links: Elephants and Tea: https://elephantsandtea.org/ BMT InfoNet: https://bmtinfonet.org/ Blood Cancer United: https://bloodcancerunited.org/ Thanks to this season's sponsors, Incyte and Sanofi. (00:00) Intro (01:01) Normalizing emotional reactions during recovery (04:22) PTSD after transplant and why it matters (08:59) Slowly letting go after transplant (13:12) Facing the worst case and choosing to move forward (13:53) The strain of worry and mental health red flags (19:31) Toxic positivity and the power of validation (20:26) How to talk with loved ones who are trying to help (22:39) Social health, connection, and friendship (26:43) Support groups, GVHD, and feeling understood (28:07) Building a survivorship "tool belt" (33:08) Why transplant never fully “stops” (36:39) A patient story about resilience and asking for help National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/Check out our valued nbmtLINK resource books, some for sale, some free as downloadable, https://www.nbmtlink.org/shop/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKFollow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/The nbmtLINK YouTube Page can be found by clicking here.This content is provided for informational purposes only and is not intended to substitute for professional medical advice, diagnosis, or treatment. It is crucial to consult directly with a qualified healthcare professional regarding any medical conditions, treatment options, or other health concerns.The views and opinions expressed by the speakers are their own and do not necessarily reflect the official policy or position of the nbmtLINK. Unless otherwise stated in an official policy, the nbmtLINK does not endorse any specific treatments, products, or services mentioned by the speakers. Reliance on any information provided is solely at your own risk.The Marrow Masters Podcast is produced by JAG Podcast Productions: https://jagpodcastproductions.com/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

On this episode of The Digital Patient, Dr. Joshua Liu, Co-founder & CEO of SeamlessMD, and colleague, Alan Sardana, chat with Veena Lingam, MD, Associate Chief Medical Information Officer at the Moffitt Cancer Center, about "The Hidden Skills Required for CMIO 4.0, the Real Risk of Consumer AI Tools in Your Org Right Now, How to Build AI Governance When There's No Blueprint, and more..."

In this episode, Rafael Rosengarten sits down with Dr. Kamal Jethwani, VP of Digital Ventures at Moffitt Cancer Center, CEO of AccelerOnc Studio, and consulting CEO of Decimal Health. With over two decades in digital health, Kamal shares how Moffitt is transforming cutting-edge oncology expertise into scalable AI-native companies, why operational implementation matters more than most founders realize, and how digital health adoption succeeds or fails inside real clinical workflows. From “concierge MVPs” to explainable AI, the conversation covers the hard-won lessons of building digital health programs at the ground level and why oncology innovation may be entering a completely new era.⁠⁠⁠⁠⁠TPM E565 highlights >⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Episode 56 links:Moffitt Cancer CenterAccelerOnc StudioDecimal Health

Listen and subscribe to Money Making Conversations on iHeartRadio, Apple Podcasts, Spotify, www.moneymakingconversations.com/subscribe/ or wherever you listen to podcasts. New Money Making Conversations episodes drop daily. I want to alert you, so you don’t miss out on expert analysis and insider perspectives from my guests who provide tips that can help you uplift the community, improve your financial planning, motivation, or advice on how to be a successful entrepreneur. Keep winning! Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Robyn Donaldson. Entrepreneur, Mentor, and Founder of Renew Construction Services & STEM Exposure

On this episode Justin records live in Tampa FL at the Moffitt Cancer Center for this special series during CancerX 2026. His guests from the Moffitt Center are Joanna Weiss, Moffitt CFO and Matthew Bednar, Moffitt VP Ambulatory & Virtual Care Operations. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

"We want to make sure that we discuss the details of the treatment and what treatments there are, whether it's an oral drug, whether it's a subcutaneous injection or an IV injection, [the patient's] potential for responding, whether this treatment is curative or supportive, and what the number of visits are. All of those different pieces of information that go into the decision-making process are really important," ONS member Sara Tinsley-Vance, PhD, APRN, AOCN®, nurse practitioner and quality-of-life researcher at Moffitt Cancer Center in Tampa, FL, told Lenise Taylor, MN, RN, AOCNS®, TCTCN™, oncology clinical specialist at ONS, during a conversation about myelodysplastic syndrome (MDS) treatment considerations. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by May 15, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge about the treatment considerations for MDS. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 411: An Overview of Myelodysplastic Syndrome for Oncology Nurses Episode 256: Cancer Symptom Management Basics: Hematologic Complications ONS Voice articles: FDA Approves Luspatercept-Aamt for Anemia in Adults With MDS Infection Prevention for Oncology Nurses Manage Cancer-Associated Anemia With Erythropoietin-Stimulating Agents Whole-Genome Sequencing May Guide Treatment Choices for AML and MDS Clinical Journal of Oncology Nursing articles:  Reducing Effects of Hospital-Associated Deconditioning in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Resilience in Older Adults Diagnosed With Cancer and Receiving Chemotherapy Targeted Drug Therapies: Beyond Blood Counts and Chemistries Oncology Nursing Forum article: Frailty in Patients With Hematologic Malignancies and Those Undergoing Transplantation: A Scoping Review ONS books:  BMTCN™ Certification Review Manual (second edition) Hematopoietic Stem Cell Transplantation: A Manual for Nursing Practice (third edition) ONS course: Hematopoietic Stem Cell Transplantation™ ONS Learning Library: Hematology, Cellular Therapy, and Stem Cell Transplantation ONS Symptom Intervention resources: Prevention of Infection: General Prevention of Infection: Transplant Aplastic Anemia and MDS International Foundation: MDS Drugs and Treatments Blood Cancer United: MDS Treatment HealthTree Foundation Myelodysplastic Syndromes Foundation To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "The goals that I try to consolidate to make sure they're consistent with the patient's goals are to improve their counts, especially the anemia or cytopenias. If they're getting blood transfusions, we want to reduce the number of transfusions that they receive because we know that's linked to reduced overall survival, and it really impacts quality of life. ... And then for high-risk patients, it's a more serious discussion because we know that they are the ones who can progress to acute myeloid leukemia (AML). And we're trying to delay progression to AML. That means we're trying to improve their survival and we're also trying to manage their cytopenias and decrease their infection risk." TS 2:28 "If we look at approvals for low-risk disease and high-risk disease, those were really made based on the Revised International Prognostic Scoring System (IPSS-R) and sometimes the International Prognostic Scoring System (IPSS). Under those classification systems, when we think of lower-risk MDS, we think of patients who are primarily anemic but don't have increased blasts in their bone marrow. ... For higher-risk MDS, we want to have that discussion with those patients because their life expectancy is much shorter than patients with lower-risk MDS. We want to see if hematopoietic stem cell transplant would be something that they would be interested in if they don't have a lot of comorbidities and are relatively healthy." TS 11:41 "There are a lot of things to consider—[patients'] blood counts, comorbidities, whether they're frail, and what their goals are. There are some patients where there's no way they would want to go through transplant. And some patients want to be cured, so it just depends on your patient." TS 14:22 "I think of hematopoietic allogeneic transplants as a treatment for more of the patients with higher-risk MDS. ... With the Molecular International Prognostic Scoring System (IPSS-M), a patient can have pretty good blood counts and not have increased blasts in the bone marrow. You could send them for a transplant referral upfront without having to give them additional treatment. ... There is a recent publication that said if a patient doesn't have more than 10% blast, you could refer to transplant as a first option. ... Also, if you had a lower-risk patient who is relatively young and doesn't have any other treatment options, this would also be a patient that you could refer to transplant to see if we could care for them, and then they wouldn't have to be getting transfused all the time." TS 21:12 "I think that we often think low-risk, no treatment needed, but it depends on the person. They often need ongoing supportive care to manage their symptoms even if they're not getting treatment. And just because we're not treating them, active observation, bringing them in to see how they're doing, if they've had infections, if their blood counts are changing, that is paying attention to them and doing something. Just because they're low-risk doesn't mean they don't need anything and we can just schedule for a one-year follow-up." TS 26:30

Caregiving is a marathon of the heart. On the latest Kidney Cancer Unfiltered, Sara Benitez, LCSW, OSW-C of Moffitt Cancer Center shares with host Annamaria Scaccia how to navigate the terrain, including:

On this episode Justin records live in Tampa FL at the Moffitt Cancer Center for this special series during CancerX 2026. His guests from the Moffitt Center are Xavier Avat, Moffitt Chief Business Officer and Dr. John Cleveland, Moffitt Center Director & Chief Scientific Officer. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

Send us Fan MailA rare diagnosis can sit quietly in the background for years, until one day a scan makes it real. That's what happened for Will Ruddell, who joins us to share his life with Neurofibromatosis Type 2 (NF2), a rare genetic disorder linked to slow-growing tumors in the brain, spine, and along nerves. Will grew up watching his father deal with serious medical issues, then found out at 26 that he also had NF2 after a migraine led to an MRI and life-changing answers. We talk honestly about what happens after the words “you have tumors” land: the scramble to find the right specialists, the stress of navigating care without insurance at first, and the reality that NF2 is still not fully understood. Will explains symptoms that shaped his everyday life, including vocal cord paralysis from a neck tumor and nerve damage that affects hand and foot movement. We also get into mobility decisions, surgery timing, and why “preparing” is hard when progression looks different for everyone. Beyond the medical side, we focus on what keeps a person steady. Will shares the role of his wife and family support, how passion and motivation help on difficult days, and where to look for NF2 resources, support groups, and research programs like the team at Moffitt Cancer Center. If you want a clearer picture of NF2 symptoms, treatment options like infusions and clinical trials, and how to show up for someone living with a rare disease, this conversation is for you. Subscribe, share this with someone who needs it, and leave a review so more people can find these stories and this information.Support the showSJ CHILDS - SOCIALS & WEBSITE MASTER LISTWEBSITES- Stream-Able Live — https://www.streamable.live-COMING SOON- The SJ Childs Global Network — https://www.sjchilds.org- The SJ Childs Show Podcast Page — https://www.sjchildsshow.comYOUTUBE- The SJ Childs Show — https://www.youtube.com/@sjchildsshow- Louie Lou (Cats Channel) — https://www.youtube.com/@2catslouielouFACEBOOK- Personal Profile — https://www.facebook.com/sara.gullihur.bradford- Business Page — https://www.facebook.com/sjchildsllc- The SJ Childs Global Network — https://www.facebook.com/sjchildsglobalnetwork- The SJ Childs Show — https://www.facebook.com/SJChildsShowINSTAGRAM- https://www.instagram.com/sjchildsllc/TIKTOK- https://www.tiktok.com/@sjchildsllcLINKEDIN- https://www.linkedin.com/in/sjchilds/PODCAST PLATFORMS- Spotify — https://open.spotify.com/show/4qgD3ZMOB2unfPxqacu3cC- Apple Podcasts — https://podcasts.apple.com/us/podcast/the-sj-childs-show/id1548143291CONTACT EMAIL- sjchildsllc@gmail.com

This episode is dedicated to my beautiful sister Sukhneil, also known as Sukhy and Pickle.Terms like hospice and palliative care can instantly make us think of worst case scenarios, but whether you are a patient or a caregiver, they should be considered a normal part of the experience offered by experts in Supportive Care Medicine.Treating a patient is not just about killing the cancer, but doing everything you can to improve their quality of life, a subject that Dr. Saima Rashid is familiar with as a specialist in palliative care, and Parmvir as a caregiver to her sister Sukhneil.Join us to learn more about how and when to request services, and the benefits that they offer.Find out about the work being done by Moffitt's Department of Supportive Care Medicine and how they can help you: https://www.moffitt.org/treatments/supportive-care-medicine/Learn more about our guests: Dr. Saima Rashid: https://www.moffitt.org/providers/saima-rashid/ Dr. Parmvir Bahia: parmvir.comThis is the second part of a conversation for the Cancer in our Community podcast, which is produced by: The Office of Community Outreach and Engagement at Moffitt Cancer Center and Artha Science Media.Follow COE: https://www.linkedin.com/in/coee-at-mcc.The featured music is: Sunlight Cascading Through the Clouds — Artificial.Music [Audio Library Release] Music provided by Audio Library Plus Watch.

One in five Americans will develop skin cancer by age 70, but Dr. Peter Kanetsky is working to tackle this through his work as an epidemiologist. This subject seems particularly apt for those of us living in “The Sunshine State” as we head into summer, but it's not just Floridians who are at risk. Join us to learn about sunscreen, shade and avoiding risky behaviors. Learn more about Peter and his work here: https://lab.moffitt.org/kanetsky/ If you want more information on how to recognize different skin cancers and learn about prevention, check out the Skin Cancer Foundation website. Learn more about our host Dr. Brandon Blue. This podcast is produced by: The Office of Community Outreach and Engagement at Moffitt Cancer Center and Artha Science Media. Follow COEE: https://www.linkedin.com/in/coee-at-mcc Track: Sunlight Cascading Through the Clouds — Artificial.Music [Audio Library Release] Music provided by Audio Library Plus Watch: https://youtu.be/mtONh3v8-mw Free Download / Stream: https://alplus.io/sunlight-cascading

Great progress with treatment options for multiple myeloma as shared by Dr. Brandon Blue and his patient Tony. Mark asks pertinent questions in this episode. Why is multiple myeloma such a rare and difficult to diagnose cancer? Let's discuss with Dr. Blue in this episode of The Mark Bishop Show. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

Great progress with treatment options for multiple myeloma as shared by Dr. Brandon Blue and his patient Tony. Mark asks pertinent questions in this episode. Why is multiple myeloma such a rare and difficult to diagnose cancer? Let's discuss with Dr. Blue in this episode of The Mark Bishop Show. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

David Sallman, MD, Moffitt Cancer Center, Tampa, FL Recorded on April 9, 2026 David Sallman, MD Associate Member, Department of Malignant Hematology Moffitt Cancer Center Tampa, FL In this exciting episode, Dr. David Sallman from Moffitt Cancer Center takes a deep dive into acute myeloid leukemia (AML) and the advances transforming patient care. The discussion spans newly approved therapies, including menin inhibitors, as well as promising approaches under investigation in clinical trials, and explores how these innovations are influencing treatment selection, transplantation, and the management of side effects and complications in today's AML landscape. Tune in today for expert insight into what's shaping the future of AML care. Additional Blood Cancer United Resources: Blood Cancer United Accredited and Non-Accredited Healthcare Professional Education Blood Cancer United Resources for Patients This episode is supported by Kura Oncology, Inc.

As Florida faces one of its worst wildfire seasons in years, a new study released at the American Association for Cancer Research annual meeting in San Diego, matches cancer rates in more than 90 thousand people over a decade to areas dealing with wildfire smoke. It finds the risk of certain cancers, including colorectal, more than doubled and risks of lung cancer nearly doubled. We speak with Matthew Schabath PhD, who leads the Cancer Epidemiology Program at Tampa's Moffitt Cancer Center, on how the researchers came up with those findings and how to apply them in your life. See omnystudio.com/listener for privacy information.

"Not every patient with myelodysplastic syndrome (MDS) is going to progress and die. Only 10%–20% of them will evolve into acute myeloid leukemia. And not all of them need blood transfusions. Some present with low platelet count. It's not just people who are anemic that have MDS—it's different depending on what type of MDS they have. These are averages. We're giving you statistics based on averages, and you're an individual, so we want to treat you as an individual," ONS member Sara Tinsley-Vance, PhD, APRN, AOCN®, nurse practitioner and quality-of-life researcher at Moffitt Cancer Center in Tampa, FL, told Lenise Taylor, MN, RN, AOCNS®, TCTCN™, oncology clinical specialist at ONS, during a conversation about myelodysplastic syndrome. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by April 17, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Nurses caring for people with myelodysplastic syndrome require knowledge of its pathophysiology, the presenting symptoms, and its diagnosis. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 339: A Lesson on Labs: How to Monitor and Educate Patients With Cancer Episode 302: Patient Navigation Eliminates Disparities in Cancer Care Episode 256: Cancer Symptom Management Basics: Hematologic Complications ONS Voice articles: Manage Cancer-Associated Anemia With Erythropoietin-Stimulating Agents Whole-Genome Sequencing May Guide Treatment Choices for AML and MDS Clinical Journal of Oncology Nursing articles:  Deciphering TP53 Mosaic Variants on Germline Biomarker Testing: Implications for Oncology Nurses Myeloid Malignancies: Recognizing the Risk of Germline Predisposition and Supporting Patients and Families Oncology Nursing Forum article: Impact of a Hematologic Malignancy Diagnosis and Treatment on Patients and Their Family Caregivers ONS book: BMTCN™ Certification Review Manual (second edition) ONS Clinical Practice resource: Genomics Taxonomy Genomics and Precision Oncology Learning Library American Cancer Society: Myelodysplastic Syndrome Prognostic Scores Aplastic Anemia and MDS International Foundation Blood Cancer United: MDS Diagnosis HealthTree Foundation Myelodysplastic Syndromes Foundation: What Is MDS? To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "In the bone marrow maturation process, you have a pluripotent stem cell. You have myeloid and lymphoid, and then on the myeloid side, you make your white blood cells, your red blood cells, and your platelets. And during that maturation process, there's this problem that arises. It's called a clonal variation. Or something goes wrong as the cells go through that process year after year. It's called ineffective hematopoiesis. ... That process of becoming mature, functioning cells, arising from that hematopoietic stem cell is broken, and this leads to low blood counts. Usually, it's anemia, so the hemoglobin is low. You can see that the mean corpuscular volume (MCV) is really high, and those are clues that a patient might have MDS—anemia with a high MCV." TS 3:05 "The International Prognostic Scoring System (IPSS) was the first way that we staged MDS into lower-risk and higher-risk disease. Now we have the IPSS-R, which is the revised system. And that was intended to be a way of classifying patients into lower-risk or higher-risk disease, where we talked about the goals being different. And it's really looking at the depth of the cytopenias, so how low are those neutrophils? How low is the hemoglobin and the platelet level? What percentage of blast does the patient have in their bone marrow? [This] gauges whether they have lower-risk or higher-risk disease. And now that we have the Molecular International Prognostic Scoring System (IPSS-M), we also take into account the variants that a patient has and that can really change whether you think they have lower-risk or higher-risk disease." TS 8:46 "During a person's lifetime, if they were a heavy smoker, we always think of lung cancer, but it can actually predispose a person to MDS. If they worked heavily in chemicals. I can remember more than one patient who worked for pesticide companies. Repeated exposure to these things that can affect our blood cells cumulatively, they can make a person more prone to MDS. Also, patients who have family members who have had bone marrow problems." TS 13:39 "The way I explain it to patients who say, 'What does dysplasia mean?' I say, 'Well, if you had a picture of a face. If the cell has too many eyes, or one eye above the other or below the other, or too many ears, or they're just disfigured. They don't look right and they don't mature normally.' And so, the descriptions I frequently see are nuclear budding and micromegakaryocytes. Once you read a lot of the reports, you start to pick out, 'Okay, these are the terms that go along with dysplastic red blood cells or dysplastic megakaryocytes,' which are your precursors to platelets." TS 21:28 "The cytogenetics and the variants—that's a hard concept to explain to patients. And staying current on how we understand the disease and how it evolves. Now we have pre-MDS states called clonal cytopenia of undetermined significance. That was new to me. And then clonal hematopoiesis of indeterminate significance. And some of those clones have other healthcare problems that go along with them." TS 30:52

In this inspiring episode, Sonia sits down with her former colleague Kristen, who shares the unexpected health journey that changed her life — and ultimately led her to launch her own podcast. What started as unexplained fatigue and sharp pain became a wake-up call that led Kristen to Moffitt Cancer Center in Tampa, where a mass was discovered in her first-ever mammogram. Praise God, it wasn't cancer, but the experience transformed her perspective on health, faith, and purpose.Kristen opens up about learning to advocate for herself in the medical system, the courage it took to seek a third opinion, and the moment she sat in the waiting room surrounded by cancer patients and felt an undeniable call from God. Out of that moment, her new podcast Chosen for This Moment, inspired by Esther 4:14 — was born.This episode is a powerful reminder to listen to your body, not delay your health screenings, and trust that God can use even the scariest seasons of life for something greater. If something has been tugging at your heart, this conversation just might be the nudge you need. Listen to Chosen For This Moment on Apple - https://podcasts.apple.com/us/podcast/chosen-for-this-moment/id1890744495Listen to Chosen For This Moment on Spotify - https://open.spotify.com/show/5ZUnriJ97a88OlT1lfXhpq?si=9d250c9c06c74bd0

What role does prostate artery embolization (PAE) play in modern prostate cancer care? In this episode of BackTable Urology, Dr. Nainesh Parikh (Interventional Radiology at Moffitt Cancer Center) and Dr. Kosj Yamoah (Radiation Oncology at Moffitt Cancer Center) join Dr. Ruchika Talwar (Vanderbilt University) to discuss how PAE could become a key adjunct in optimizing radiation therapy outcomes. --- Get the BackTable app https://www.backtable.com/app --- Timestamps 00:00 - Introduction01:44 - Why Use PAE in Cancer04:08 - Neoadjuvant and Salvage Use07:26 - Radiation Planning Benefits12:51 - PAE vs. Surgery18:36 - SBRT Access20:48 - Current Evidence and Trials25:29 - Patient Selection32:18 - PAE After Radiation36:56 - When to Avoid PAE40:29 - Long-Term Implications44:28 - Conclusions --- More about this episode They review how PAE can improve lower urinary tract symptoms and reduce prostate volume, potentially optimizing patients for radiation therapy, including stereotactic body radiotherapy (SBRT) and brachytherapy. The discussion highlights early clinical data and patient selection considerations such as gland size and symptom burden. Finally, they examine post-radiation applications, technical challenges, and current limitations, emphasizing the need for larger, multicenter trials to better define PAE's role in prostate cancer treatment pathways. --- Resources Prostate Artery Embolization in the Setting of Prostate Cancer: Review and Opinionhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11775958/

In this episode, Cassandra Vonnes, DNP, GNP-BC, APRN, AOCNP, CPHQ, FAHA, a Gerontological Nurse Practitioner, and member of the GAPNA Communication Team, talks with Terry Fulmer, PhD, RN, FAAN, President Emerita of the John A. Hartford Foundation in New York City, NY. Dr. Fulmer discusses the start and early years of her nursing career, including her family history with the profession. Throughout the discussion, she identifies key mentors and collaborators along her journey, and their impact on not only her success, but the specialty of geriatric nursing as well. Dr. Fulmer highlights the benefits and importance of the Nurses Improving Care for Health System Elders – or NICHE – program and the Age-Friendly Health Systems movement as the driving force behind their development. Terry Fulmer, PhD, RN, FAAN, is President Emerita of the John A. Hartford Foundation in New York City, New York. She currently serves on various boards, including Springer Publishing and Bassett Medical Center, and is Vice Chair of the VA Special Medical Advisory Group. Cassandra Vonnes, DNP, GNP-BC, APRN, AOCNP, CPHQ, FAHA, is the Nurses Improving Care for Healthsystem Elders (NICHE) Coordinator, Geriatric Oncology, at the Moffitt Cancer Center, in Tampa, Florida. She is a member of the Gerontological Advanced Practice Nurses Association Communication Team and is a host of the GAPNA Chat podcast series.Discover GAPNA: https://www.gapna.org/Production management by Anthony J. Jannetti, Inc., for the Gerontological Advanced Practice Nurses Association.Opening Music by:Optimistic / Inspirational by Mixaund | https://mixaund.bandcamp.com
Music promoted by https://www.free-stock-music.comClosing Music by:Scott Holmes.http://www.scottholmesmusic.com

In this episode, Cassandra Vonnes, DNP, GNP-BC, APRN, AOCNP, CPHQ, FAHA, a Gerontological Nurse Practitioner, and member of the GAPNA Communication Team, talks with Grace Sun, DNP, APRN, FNP-BC, an Assistant Dean of APRN Programs at the University of Texas at Tyler, and currently serves as Secretary of the National Organization of Nurse Practitioner Faculties.  Dr. Sun shares her journey integrating artificial intelligence into nursing education and practice. She explores changes in how students are taught, how AI can enhance but not replace clinical judgment, and practical advice for nurse practitioners and students to confidently navigate this rapidly evolving digital landscape. Dr. Sun also discusses the ethical considerations and leadership roles nurse practitioners can take in shaping the future of AI in health care.Grace Sun, DNP, APRN, FNP-BC, is an Assistant Dean of APRN Programs at the University of Texas at Tyler and currently serves as Secretary of the National Organization of Nurse Practitioner Faculties.Cassandra Vonnes, DNP, GNP-BC, APRN, AOCNP, CPHQ, FAHA, is the Nurses Improving Care for Healthsystem Elders (NICHE) Coordinator, Geriatric Oncology, at the Moffitt Cancer Center, in Tampa, Florida. She is a member of the Gerontological Advanced Practice Nurses Association Communication Team and is a host of the GAPNA Chat podcast series.Discover GAPNA: https://www.gapna.org/Production management by Anthony J. Jannetti, Inc., for the Gerontological Advanced Practice Nurses Association.Opening Music by:Optimistic / Inspirational by Mixaund | https://mixaund.bandcamp.com
Music promoted by https://www.free-stock-music.comClosing Music by:Scott Holmes.http://www.scottholmesmusic.com

Dr Bijal Shah from Moffitt Cancer Center in Tampa, Florida, discusses the role of BiTEs in the management of ALL.CME information and select publications here.

In this episode, Cassandra Vonnes, DNP, GNP-BC, APRN, AOCNP, CPHQ, FAHA, a Gerontological Nurse Practitioner, and member of the GAPNA Communication Team, talks with Leslie Beth Eber, MD, CMD,  the Medical Director for Rocky Mountain Senior Care, in Englewood, Colorado, and the current President-Elect of the Post-Acute and Long-Term Care Medical Association. Dr. Eber reflects on how her mother's legacy of advocacy and priorities shaped her own commitment to improving care for older adults. She discusses the key challenges facing the post-acute and long-term care sector, including workforce strain and the need for clearer priorities in a politically unsettled healthcare landscape. She also explores the trifecta of influence: value, meaning, and efficacy, and shares her vision for deeper collaboration between the Post-Acute and Long-Term Care Medical Association (PALTmed) and GAPNA.Leslie Beth Eber, MD, CMD, is the Medical Director for Rocky Mountain Senior Care, in Englewood, Colorado, and currently serves as the President-Elect of the Post-Acute and Long-Term Care Medical Association.Cassandra Vonnes, DNP, GNP-BC, APRN, AOCNP, CPHQ, FAHA, is the Nurses Improving Care for Healthsystem Elders (NICHE) Coordinator, Geriatric Oncology, at the Moffitt Cancer Center, in Tampa, Florida. She is a member of the Gerontological Advanced Practice Nurses Association Communication Team and is a host of the GAPNA Chat podcast series.Discover GAPNA: https://www.gapna.org/Production management by Anthony J. Jannetti, Inc., for the Gerontological Advanced Practice Nurses Association.Opening Music by:Optimistic / Inspirational by Mixaund | https://mixaund.bandcamp.com
Music promoted by https://www.free-stock-music.comClosing Music by:Scott Holmes.http://www.scottholmesmusic.com

I sit down with Stefania Alastre as we discuss her role as Genetic Counselor at the Moffitt Cancer Center, as well as Assistant Professor at the University of South Florida genetic counseling program, and her role as Certified Medical Translator.  We also talk about worm cloning, soccer and the X-Men.  Enjoy!

On this episode Justin Barnes records live in Tampa FL at the Moffitt Cancer Center for this special series during CancerX 2026. He brings back Dr. Kamal Jethwani, VP Digital Ventures & CEO AccelerOnc and Dr. Nainesh Parikh, VP Chief Expansion & Partner Officer from the Moffitt Center to discuss more on this year's CancerX Accelerator.

Cancer treatments come in many forms: surgery, chemotherapy, radiation therapy and more recently immunotherapy. While there are many types of treatment, they all undergo the same important checks to assess effectiveness and safety through clinical trials. But what is a clinical trial? Why should patients participate? And how can patients trust that they are the best option for them? To answer this and more, we spoke with Research Community Health Educator Delilah Hernandez. For further information about clinical trials, check out the Moffitt website: https://www.moffitt.org/clinical-trials-research/clinical-trials/ Learn more about Delilah's work with Dr. Susan Vadaparampil on the team's website: https://lab.moffitt.org/crisp/meet-our-team/ or follow her on LinkedIn: https://www.linkedin.com/in/delilah-hernandez-mhs-169a10183/ Learn more about our host Dr. Brandon Blue. This podcast is produced by: The Office of Community Outreach and Engagement at Moffitt Cancer Center and Artha Science Media. Follow COE: https://www.linkedin.com/in/coee-at-mcc Track: Sunlight Cascading Through the Clouds — Artificial.Music [Audio Library Release] Music provided by Audio Library Plus Watch: https://youtu.be/mtONh3v8-mw Free Download / Stream: https://alplus.io/sunlight-cascading

Computing resources are no longer just pieces of tech—they're scientific instruments. Moffitt Cancer Center's Jarett DeAngelis, director of scientific information technology, and Shane Corder, senior HPC engineer, join cohost Jessica StLouis, senior scientific consultant at BioTeam, to discuss new approaches changing access to HPC resources and how platforms like Open OnDemand are simplifying the HPC experience for those unfamiliar with the system. They also share their thoughts on the future of HPC resources, what the Moffitt Cancer Center is planning, and what they expect to see in the field in the coming years. Links from this episode:  Bio-IT World BioTeam Bio-IT World Europe Moffitt Cancer Center Bio-IT World's Trends from the Trenches podcast delivers your insider's look at the science, technology, and executive trends driving the life sciences through conversations with industry leaders.

On this episode Justin records live in Tampa FL at the Moffitt Cancer Center for this special series during CancerX 2026. His first guests, from the Moffitt Center are Dr. Kamal Jethwani, VP Digital Ventures & CEO AccelerOnc, Dr. Nainesh Parikh, VP Chief Expansion & Partner Officer, and Dr. Patrick Hwu, President & CEO. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

In this episode, Dr. Cassandra Vonnes, DNP, GNP-BC, APRN, AOCNP, CPHQ, FAHA, a Gerontological Nurse Practitioner, and member of the GAPNA Communication Team, talks with Dr. Michelle Moccia, DNP, ANP-BC, GS-C, an Adult Geriatric Nurse Practitioner, and Chair of GAPNA's Chapter Leadership Committee.  Dr. Moccia reflects on her 50-year nursing career, highlighting her pioneering work in geriatric care, including developing Michigan's first Level 1 accredited geriatric emergency department. She discusses community collaborations to improve emergency preparedness in nursing homes and initiatives to ensure patient-centered care through advanced directives and training. The conversation emphasizes compassionate, consistent care and practical strategies to better support older adults across healthcare settings.Dr. Michelle Moccia, DNP, ANP-BC, GS-C, is an Adult Geriatric Nurse Practitioner, in Livonia Michigan, and serves as GAPNA's Chapter Leadership Chair.  Dr. Cassandra Vonnes, DNP, GNP-BC, APRN, AOCNP, CPHQ, FAHA, is the Nurses Improving Care for Healthsystem Elders (NICHE) Coordinator, Geriatric Oncology, at the Moffitt Cancer Center, in Tampa, Florida. She is a member of the Gerontological Advanced Practice Nurses Association Communication Team and is a host of the GAPNA Chat podcast series.Discover GAPNA: https://www.gapna.org/Production management by Anthony J. Jannetti, Inc., for the Gerontological Advanced Practice Nurses Association.Opening Music by:Optimistic / Inspirational by Mixaund | https://mixaund.bandcamp.com
Music promoted by https://www.free-stock-music.comClosing Music by:Scott Holmes.http://www.scottholmesmusic.com

In this episode, Dr. Cassandra Vonnes, a Gerontological Nurse Practitioner, and member of the GAPNA Communication Team, talks with Dr. Kimberly Posey, the Coordinator of the Executive Nurse DNP Program and MSN Nursing Education Program at Texas Christian University, in Fort Worth, TX, and currently serves as GAPNA's President.  Dr. Posey shares her unconventional path from a technical career at IBM to discovering her passion for nursing and geriatric care. She discusses community-based initiatives, including a foot care clinic for unhoused older adults, and shares insights from her research on nurse practitioner job satisfaction and interprofessional education in long-term care. She also highlights her policy work on the Texas Nursing Facility Administrators Advisory Committee, emphasizing the importance of advocacy, mentorship, and advancing high-quality, compassionate care for older adults.Dr. Kimberly Posey, PhD, DNP, APRN, AGPCNP, GS-C, FAANP, is the Coordinator of the Executive Nurse DNP Program and MSN Nursing Education Program at Texas Christian University, in Fort Worth, TX, and currently serves as GAPNA's President.  Dr. Cassandra Vonnes, DNP, GNP-BC, APRN, AOCNP, CPHQ, FAHA, is the Nurses Improving Care for Healthsystem Elders (NICHE) Coordinator, Geriatric Oncology, at the Moffitt Cancer Center, in Tampa, Florida. She is a member of the Gerontological Advanced Practice Nurses Association Communication Team and is a host of the GAPNA Chat podcast series.Discover GAPNA: https://www.gapna.org/Production management by Anthony J. Jannetti, Inc., for the Gerontological Advanced Practice Nurses Association.Opening Music by:Optimistic / Inspirational by Mixaund | https://mixaund.bandcamp.com
Music promoted by https://www.free-stock-music.comClosing Music by:Scott Holmes.http://www.scottholmesmusic.com

Dr. Sonam Puri discusses the full update to the living guideline on stage IV NSCLC with driver alterations. She shares a new overarching recommendation on biomarking testing and explains the new recommendations and the supporting evidence for first-line and subsequent therapies for patients with stage IV NSCLC and driver alterations including EGFR, MET, ROS1, and HER2. Dr. Puri talks about the importance of this guideline and rapidly evolving areas of research that will impact future updates. Read the full living guideline update "Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.0" at www.asco.org/thoracic-cancer-guidelines TRANSCRIPT This guideline, clinical tools and resources are available at www.asco.org/thoracic-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology,  https://ascopubs.org/doi/10.1200/JCO-25-02822    Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I'm interviewing Dr. Sonam Puri from Moffitt Cancer Center, co-chair on "Therapy for Stage IV Non-Small Cell Lung Cancer with Driver Alterations: ASCO Living Guideline, Version 2026.3.0." It's great to have you here today, Dr. Puri. Dr. Sonam Puri: Thanks, Brittany. Brittany Harvey: And then just before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Puri, who has joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then, to dive into the content that we're here today to talk about, Dr. Puri, this living clinical practice guideline for systemic therapy for patients with stage IV non-small cell lung cancer with driver alterations is updated on an ongoing basis. So, what data prompted this latest update to the recommendations? Dr. Sonam Puri: So Brittany, non-small cell lung cancer is one of the fastest-moving areas in oncology right now, particularly when it comes to targeted therapy for driver alterations. New data are emerging continuously from clinical trials, regulatory approvals, real-world experience, which is exactly why these are living guidelines. The goal is to rapidly integrate important advances as they happen, rather than waiting for years for a traditional update. Since the last full update of the ASCO Stage IV Non-small Cell Lung Cancer Guideline with Driver Alterations published in 2024, there have been seven new regulatory approvals and changes in first-line therapy for some driver alterations. [This version] of the "Stage IV Non-small Cell Lung Cancer Guidelines with Driver Alterations" represents a full update, which means that the panel reviewed and refreshed every applicable section of the guideline to reflect the most current evidence across therapies including sequencing and clinical decision-making. This is to ensure that clinicians have up-to-date practical guidelines that keep pace with how quickly the field is evolving. Brittany Harvey: Absolutely. As you mentioned, this is a very fast-moving space and this full update helps condense all of those versions that the panel reviewed before into one document, along with additional approvals and new trials that you reviewed during this time period. So then, the first aspect of the guideline is there's a new overarching recommendation on biomarker testing. Could you speak a little bit to that updated recommendation? Dr. Sonam Puri: Yeah, definitely. So the panel has discussed and provided recommendations on comprehensive biomarker testing and its importance in all patients diagnosed with non-small cell lung cancer. Ideally, biomarker testing should include a broad-based next-generation sequencing panel, rather than single-gene tests, along with immunohistochemistry for important markers such as PD-L1, HER2, and MET. These results really drive treatment decisions, both in frontline settings for all patients diagnosed with non-small cell lung cancer and in subsequent line settings for patients with non-small cell lung cancer harboring certain targetable alterations. Specifically in the frontline setting, it helps determine whether a patient should receive upfront targeted therapy or immunotherapy-based approach. We now have strong data that shows that complete molecular profiling results before starting first-line therapy is associated with better overall survival and actually more cost-effective care. Using both tissue and blood-based testing can improve likelihood of getting actionable results in a timely way, and we've also provided guidance on platforms that include RNA sequencing, which are specifically helpful for identifying gene fusions that might be otherwise missed with other platforms. On the flip side, outside of a truly resource-limited setting, single-gene PCR testing really should not be routine anymore. This is what the panel recommends. It's less sensitive and inefficient and increases the risk of missing important actionable alterations. Brittany Harvey: Understood. I appreciate you reviewing that recommendation. It really helps identify critical individual factors to match the best treatment option to each individual patient. So then, following that recommendation, what are the updated recommendations on first-line therapy for patients with stage IV non-small cell lung cancer with a driver alteration? Dr. Sonam Puri: Since the last full update in 2024, there have been four additional interim updates which were published across 2024 and 2025. Compared to the last version, there have been several updates which have been included in this full update. One of the most important shifts has been in first-line treatment of patients with non-small cell lung cancer harboring the classical, or what we call as typical, EGFR mutation. The current version of the recommendation is based on the updated survival data from the phase III FLAURA2 and MARIPOSA studies, based on which the panel recommended to offer either osimertinib combined with platinum-pemetrexed chemotherapy or the combination of amivantamab plus lazertinib in the first-line treatment of classical EGFR mutations. And these recommendations, as I mentioned, are grounded in the results of the FLAURA2 and MARIPOSA trials, both of which demonstrated improvement in progression-free survival and overall survival compared to osimertinib alone in patients with common EGFR mutations. That being said, the panel actually spent significant time discussing the toxicities associated with these treatments as well. These combination approaches come with higher toxicity, longer infusion time, increased treatment frequency. So while combination therapy is now recommended as preferred, the panel has recommended that osimertinib monotherapy remains a reasonable option, particularly for patients with poor performance status and for those who are not interested in treatment intensification after knowing the risks and benefits. Brittany Harvey: Absolutely. It's important to consider both those benefits and risks of those adverse events that you mentioned to match appropriately individualized patient care. So then, beyond those recommendations for first-line therapy, what is new for second-line and subsequent therapies? Dr. Sonam Puri: So this is a section that saw several major updates, particularly again in the EGFR space. The first was an update on treatment after progression on osimertinib for patients with classical EGFR mutation. Here the panel recommends the combination of amivantamab plus chemotherapy, and this recommendation was based on the phase III MARIPOSA-2 trial, which compared amivantamab plus chemotherapy with chemotherapy alone with progression-free survival as the primary endpoint. The study met its primary endpoint, showing an improvement in median PFS with the combination of amivantamab plus chemotherapy compared to chemotherapy alone. And as expected, the combination was associated with higher toxicity. So, although the panel recommends this regimen, the panel emphasizes that patients should be counseled on the side effects which may be moderate to severe with the combination therapy approach. In addition, a new recommendation was added for patients who are not candidates for amivantamab plus chemotherapy. In those cases, platinum-based chemotherapy with or without continuation of osimertinib may be offered, and the option of continuing osimertinib with chemotherapy was recommended and supported by data from a recently presented phase III COMPEL study, which randomized 98 patients with EGFR exon 19 deletion or L858R-mutated advanced non-small cell lung cancer who had experienced no CNS progression on first-line osimertinib, and these patients were randomized to receive platinum-pemetrexed chemotherapy with osimertinib or placebo. Although this study was small, it demonstrated a PFS benefit with continuation of osimertinib with chemotherapy, and this approach may be appropriate for patients without CNS progression who prefer or require alternatives to more intensive treatment strategies. Next was an update on options for patients with EGFR-mutated lung cancer after progression on osimertinib and platinum-based chemotherapy. Here the panel recommended that for patients whose disease has progressed after both osimertinib and platinum-based chemotherapy, a new drug known as datopotamab deruxtecan can be offered as a treatment option. And this treatment recommendation was based on evaluation of pooled data from the TROPION-Lung01 and TROPION-Lung05 study, in which in the pooled analysis about 114 patients with EGFR-mutant non-small cell lung cancer were treated with Dato-DXd, 57% of whom had received three or more prior lines of treatment, and what was observed was an overall response rate of 45% with a median duration of response of 6.5 months. So definitely promising results. Next, we focused on updates to subsequent therapy options for patients with another type of EGFR mutation known as EGFR exon 20 insertion mutations. In this section, the panel added sunvozertinib as a subsequent line option after progression on platinum-based chemotherapy with or without amivantamab. Sunvozertinib is an oral, irreversible, and selective EGFR tyrosine kinase inhibitor with efficacy demonstrated in the phase II WU-KONG6 study conducted in Chinese patient population. In this study, amongst 104 patients with platinum-pretreated EGFR exon 20 mutated non-small cell lung cancer, the observed response rate was 61%. Staying in the EGFR space, the panel added a recommendation for patients with acquired MET amplification following progression on EGFR TKI therapy. In these situations, the panel recommended that treatment may be offered with osimertinib in combination with either tepotinib or savolitinib. As our listeners may know, MET amplification occurs in approximately 10% to 15% of patients with EGFR-mutated non-small cell lung cancer when they progress on third-generation EGFR TKIs, and detection of MET amplification is done with various methods, such as tissue-based methods like FISH, NGS, and IHC, as well as ctDNA-based NGS with variable cut-offs. Over the last few years, several studies have informed this recommendation. I'm going to be discussing some of them. In the phase II ORCHARD trial, 32 patients with MET-amplified non-small cell lung cancer after progression on first-line osimertinib were evaluated, where the combination of osimertinib plus savolitinib achieved an overall response rate of 47% with a duration of response of 14.5 months. More recently, the phase II SAVANNAH trial reported outcomes in 80 patients with MET-amplified tumors after progression on osimertinib, and in this patient population, the combination of savolitinib and osimertinib achieved an overall response rate of 56% with a median PFS of 7.4 months. And lastly, the phase II single-arm INSIGHT 2 trial assessed the efficacy of osimertinib plus tepotinib in patients with advanced EGFR-mutant non-small cell lung cancer who had disease progression following first-line osimertinib therapy. And in this study, in a cohort of 98 patients with MET-amplified tumors confirmed by central testing, the overall response rate with the combination was 50% with a duration of response of 8.5 months. So definitely informing this guideline recommendation. Next, we had an update on recommendation in patients with ROS1-rearranged non-small cell lung cancer. For patients with ROS1-rearranged non-small cell lung cancer, the panel recommended specifically for patients who progressed after first-line ROS1 TKIs, the addition of taletrectinib as a new option alongside repotrectinib. And this recommendation was based on analysis of the results of the TRUST-I and TRUST-II studies, which showed that amongst 113 tyrosine kinase inhibitor-pretreated patients, taletrectinib achieved a confirmed overall response rate of 55.8% with a median duration of response of 16.6 months and a median PFS of 9.7 months, a very promising agent. Finally, for patients with HER2 exon 20 mutated non-small cell lung cancer, the panel added two new oral HER2 tyrosine kinase inhibitors, zongertinib and sevabertinib, as options in addition to T-DXd and after exposure to T-DXd. These recommendations are based on early phase data from two trials: the phase I Beamion LUNG-01 study, which evaluated zongertinib, and the phase I/II SOHO-01 study that evaluated sevabertinib. In this study, zongertinib demonstrated an overall response rate of 71% in previously treated patients, with an overall response rate of 48% amongst patients who had received prior HER2-directed ADCs including T-DXd. Sevabertinib in its early phase study showed an overall response rate of 64% in previously treated but HER2 therapy-naive patients, and an overall response rate of 38% in patients previously exposed to HER2-directed therapy. The panel believes that both agents had manageable toxicity profile and represent meaningful new options for this patient population. Brittany Harvey: Certainly, it's an active space of research, and I appreciate you reviewing the evidence underpinning all of these recommendations for our listeners. So, it's great to have these new options for patients in the later-line settings. And given all of these updates in both the first and the later-line settings, what should clinicians know as they implement this latest living guideline update, and how do these changes impact patients with non-small cell lung cancer? Dr. Sonam Puri: Some great questions, Brittany. I think for clinicians when implementing this update, I think about two practical steps. First is reiterating the importance of comprehensive biomarker testing. That is the only way to identify key drivers and resistance mechanisms that we are now targeting. And second, picking a first-line strategy that balances efficacy and toxicity and patient preference for your specific patient. I think informed decision-making, shared decision-making is more important than any time right now. It has always been important, but definitely very important now. For patients, this guideline brings recommendations on more personalized treatment options for both first-line and post-progression settings, which potentially means better outcomes. But it is also very important for our patients to continue to have informed conversations about side effects, time commitment, and what matters most to them with their providers. The panel in this version of the guideline specifically acknowledges the real-world barriers that prevent patients from receiving guideline-concordant therapy, including challenges with access to comprehensive molecular testing and treatment availability, and the panel emphasizes on the importance of shared decision-making, and we provide practical discussion points to help clinicians navigate these conversations with the patient. In addition, the panel has also addressed common real-world clinical complexities, such as treating elderly or frail patients, managing multiple chronic conditions, considerations around pregnancy and fertility, and certain disease scenarios such as oligoprogression or oligometastatic disease. And where available, the guideline summarizes this existing data to support informed individual decision-making in these complex situations. Brittany Harvey: Shared decision-making is really paramount, especially with all of the options and weighing the risks and benefits and considering the individual circumstances of each patient that comes before a clinician. We've talked a lot about all of the new studies that the panel has reviewed, but what other studies or areas of research is the panel examining for future updates to this living guideline as it continues to be updated on an ongoing basis? Dr. Sonam Puri: Yes, definitely, so much to look forward to, right? Looking ahead, the panel is closely monitoring several rapidly evolving areas that are likely to shape future updates of the guideline. This includes emerging data from ongoing later-phase studies, particularly the studies that are evaluating these new targeted agents moving to earlier lines of therapy, alongside studies evaluating additional combination strategies or more refined approaches to treatment sequencing. We're also closely watching advances in biomarker testing, the evolving understanding of resistance mechanisms, development of new targets, and promising therapeutic agents. I think ultimately the living guideline exists to help clinicians and patients navigate this rapidly evolving field, and we would like to ensure that scientific advances are rapidly translated into better, more personalized patient care. Brittany Harvey: Definitely. We'll look forward to those updates from those ongoing trials and future areas of research that you mentioned to provide better options for patients with non-small cell lung cancer and a driver alteration. So I want to thank you so much for your work to rapidly and continuously update this guideline, and thank you for your time today, Dr. Puri. Dr. Sonam Puri: Thanks so much. Thanks so much for the opportunity. Brittany Harvey: And finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/thoracic-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app available in the Apple App Store or the Google Play Store. There's also a companion episode with Dr. Reuss on the related living guideline on stage IV non-small cell lung cancer without driver alterations that listeners can find in their feeds as well. And if you've enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

A cancer diagnosis can feel overwhelming - but patients are not powerless. In this episode, Dr. Nainesh Parikh of Moffitt Cancer Center explains how patients and families can better advocate for themselves, navigate complex healthcare systems, and get connected to the right care at the right time.

In this episode, Dr. Cassandra Vonnes, DNP, GNP-BC, APRN, AOCNP, CPHQ, FAHA, a Gerontological Nurse Practitioner, and member of the GAPNA Communication Team, talks with MJ Henderson, MS, RN, GNP-BC, a Gerontological Nursing Consultant and a Retired Assistant Professor at MGH Institute of Health Professions, in Boston Massachusetts.Together, they discuss GAPNA's evolution toward inclusivity across all advanced practice nursing roles, the importance of student engagement in professional organizations, and Ms. Henderson's continued commitment to supporting older adults through the Village to Village Network. Henderson shares her passion for gerontological nursing, lifelong learning, and community connection. MJ Henderson, MS, RN, GNP-BC, is a Gerontological Nursing Consultant and a Retired Assistant Professor at MGH Institute of Health Professions, in Boston Massachusetts.Dr. Cassandra Vonnes, DNP, GNP-BC, APRN, AOCNP, CPHQ, FAHA, is the Nurses Improving Care for Healthsystem Elders (NICHE) Coordinator, Geriatric Oncology, at the Moffitt Cancer Center, in Tampa, Florida. She is a member of the Gerontological Advanced Practice Nurses Association Communication Team and is a host of the GAPNA Chat podcast series. Discover GAPNA: https://www.gapna.org/Production management by Anthony J. Jannetti, Inc., for the Gerontological Advanced Practice Nurses Association.Opening Music by:Optimistic / Inspirational by Mixaund | https://mixaund.bandcamp.com
Music promoted by https://www.free-stock-music.comClosing Music by:Scott Holmes.http://www.scottholmesmusic.com

Prof Claire Harrison from Guy's and St Thomas' NHS Foundation Trust in London, Dr Andrew T Kuykendall from Moffitt Cancer Center, Dr Stephen T Oh from the Washington University School of Medicine, Dr Jeanne Palmer from the Mayo Clinic School of Medicine and Dr Raajit K Rampal from Memorial Sloan Kettering Cancer Center discuss recent updates on available and novel treatment strategies for myelofibrosis and systemic mastocytosis.CME information and select publications here.

In today's episode, the discussion features Jonathan R. Strosberg, MD, a professor and leader in the Neuroendocrine Tumor Division and the Department of Gastrointestinal Oncology Research Program at Moffitt Cancer Center in Tampa, Florida, who reviewed the clinical implications of peptide receptor radionuclide therapy (PRRT) with 177Lu-edotreotide (ITM-11) for patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs), drawing on efficacy and safety findings from the phase 3 COMPETE trial (NCT03049189). 

Join host Dr. Nikolaos Papadantonakis as he welcomes Dr. Colin Vale from Winship Cancer Institute of Emory University and Dr. Nancy Luna Torres from Moffitt Cancer Center to discuss the fundamentals of allogeneic hematopoietic stem cell transplantation for MDS patients.  Our experts break down complex medical concepts into easy-to-understand language, helping patients make informed decisions about this important treatment option.

In this follow-up episode,  Dr. Nikolaos Papadantonakis continues the conversation with Dr. Colin Vale from Winship Cancer Institute of Emory University and Dr. Nancy Luna Torres from Moffitt Cancer Center, diving deeper into advanced transplant topics. This episode is ideal for patients and families who want to understand the nuances of transplant care and post-transplant management.

Dr. Olga Klinkova, Infectious Diseases Clinician at the Moffitt Cancer Center and Research Institute, presents a talk on Candida Infections. Dr. Klinkova begins by discussing the epidemiology of Candida. She then touches upon the importance of biofilms on the pathogenicity of Candida strains. Next, she breaks down the individual Candida species and highlights unique characteristics of each one. Following this, she presents several unique cases of human Candida infections and through the cases, highlights Candida auris, oropharyngeal candidiasis, esophageal disease, and candidemia. Lastly, she closes with information on hepatosplenic candidiasis.

In this episode, we sit down with Dr. Joseph Pidala from the Moffitt Cancer Center to discuss chronic graft-versus-host disease (GVHD), a complex condition affecting many stem cell transplant survivors. We focus on the latest prevention strategies, treatment innovations, and the critical role that clinical trials continue to play in advancing care.We begin with promising news around prevention. Dr. Pidala shares data from the BMT CTN 1703 trial, which compared conventional GVHD prevention to a newer approach using post-transplant cyclophosphamide (PTCy). This newer strategy significantly reduced the incidence of both acute and chronic GVHD, signaling a major step forward in preventing this debilitating condition.Despite advancements, many patients still experience chronic GVHD, which drives the need for new treatments. We explore several groundbreaking clinical trials that are rethinking traditional steroid-heavy treatment protocols. One study is testing Rezurock (Belumosudil) as a preemptive treatment during early symptoms, while another is investigating whether Jakafi (Ruxolitinib) can be used as a first-line treatment to reduce steroid reliance. These trials challenge old norms and aim to improve long-term outcomes.We also take a look at the four FDA-approved therapies currently available for steroid-refractory chronic GVHD: Ibrutinib, Jakafi, Rezurock, and the most recent addition, Axatilimab (Niktimvo). These drugs, each with different mechanisms and side effects, give patients and clinicians more flexibility than ever before. We touch on other widely used therapies like ECP (photopheresis), which, while not FDA-approved, remain an important part of care.Patient involvement is a key theme throughout. Dr. Pidala emphasizes that progress would be impossible without those who enroll in clinical trials, sharing inspiring examples of patients who benefited from early access to now-approved drugs. He encourages patients to advocate for themselves and speak up about symptoms, improvements, or quality of life changes. Patient-reported outcomes are becoming standard in trials, offering critical insight into treatment success from the patient's perspective.Dr. Pidala also highlights the importance of addressing GVHD holistically. Beyond core treatments, supportive care—including help with dry eyes, itching, joint mobility, pain, and mental health—is crucial to improving day-to-day life. He stresses that long-term recovery is possible and shares a moving story of a young woman with severe GVHD who, through persistent treatment, regained functionality and returned to a fulfilling life.We close with advice for patients: be proactive, informed, and open to trial participation. And when seeking information on trials, always start by asking your clinical team—they'll know what's available and suitable for your specific situation. Above all, Dr. Pidala leaves us with a message of hope—there's real progress being made, and the future looks brighter than ever.Thanks to our Season 19 sponsors, Incyte and Sanofi.https://incyte.com/https://www.sanofi.com/en00:40 – Introduction to Dr. Joseph Pidala01:21 – New GVHD Prevention Approaches02:44 – Why Clinical Trials Matter03:22 – Challenging Steroid-Based Treatment Norms06:14 – Timeline for New Treatment Results07:02 – FDA-Approved Drugs for Chronic GVHD09:09 – Individualized Treatment Approaches10:69 – The Role of Patient-Reported Outcomes13:44 – Symptom Management and Supportive Care15:20 – Addressing Mental Health in GVHD17:30 – Inspirational Patient Story21:12 – Advice for GVHD Patients23:02 – How to Find Clinical Trials25:06 – Final Thoughts and Message of Hope National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKFollow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/The nbmtLINK YouTube Page can be found by clicking here.To participate in the GVHD Mosaic, click here: https://amp.livemosaics.com/gvhd Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

On this episode Justin records live at HLTH25 in Las Vegas. Stay tuned for the next few weeks to hear all his guests. This week Justin talks to Michael Silverstein, Managing Partner of Healthcare IT & Life Sciences, DRI and Kamal Jethwani, MD, Co-Founder, Decimal.health and VP, Digital Ventures, Moffitt Cancer Center. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

On this episode Justin Barnes records live at HLTH25 in Las Vegas. Stay tuned for the next few weeks to hear all his guests. This week Justin talks to Nainesh Parikh, MD, MBA, VP, Chief Clinical Expansion & Partnerships Officer at Moffitt Cancer Center, and Rich Scarfo, President at HLTH, Inc. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

12 proven business models that separate successful products from failures!Product Manager Brian Orlando & Enterprise Business Agility Consultant Om Patel examine 12 real-world business models with real examples of the companies that employ them!Based on "The Art of Profitability" by Adrian Slywotzky (2002), this part-1-of-2 podcast covers:• Customer Solution Model (Palantir, SAP, Salesforce)• Product Pyramid (Apple, Tesla, GM)• Multi-Component Pricing (Uber, Coca-Cola)• Switchboard Platforms (Uber, Airbnb, eBay)• Time & Materials (Consulting firms)• Blockbuster Model (Pharma, Netflix)• Profit Multiplier (Microsoft, Disney)• Entrepreneurial Model• Specialist Model (Mayo Clinic, Agile Coaches)• Installed Base (Printers, Razors, K-Cups)• De Facto Standard (Windows, Adobe PDF)• Brand Model (Apple, Nike, BMW)Perfect for product managers, agile coaches, startup founders, and business leaders trying to understand which revenue model fits their product strategy.

In this episode of the Oncology Brothers podcast, we are joined by esteemed hematologists Dr. Onyee Chan from Moffitt Cancer Center and Dr. Fadi Haddad from MD Anderson to discuss the management of side effects associated with tyrosine kinase inhibitors (TKIs) used in the treatment of chronic myeloid leukemia (CML). Join us as we delve into: • An overview of the different generations of TKIs, including imatinib, dasatinib, nilotinib, bosutinib, ponatinib, and asciminib. • Common class-wide toxicities such as fatigue, hypertension, gastrointestinal symptoms, and cytopenias. • Unique side effects associated with each TKI and strategies for dose optimization. • The importance of patient education and monitoring to ensure effective management of side effects. Don't forget to check out our other ToxCheck episodes on antibody drug conjugates, CAR-T therapies, and more! Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Subscribe to the Oncology Brothers for more discussions on bridging the gap between academic research and community practice in cancer care! #CML #TKI #ToxCheck #Hematology #OncologyBrothers #PrecisionMedicine

Gregorio Uglioni sits down with senior customer experience manager Patty Soltis to explore the intricate dynamics of convincing the C-suite to embrace customer experience initiatives. Patty shares invaluable insights on aligning CX efforts with business strategies, understanding executive priorities, and demonstrating the true value of CX to drive profitability. This episode is a must-listen for anyone looking to bridge the gap between customer experience and executive buy-in. About Patty Soltis Over three decades of experience, Patty has been a practitioner, consultant, and analyst in CX. She led dysfunctional organizations through change management to profitability. She found significant financial benefits with more profitable sales and lower expenses using the CX discipline. Using customer-centric business strategies, Patty created customer centric cultures, advised organizations to adopt CX, and analyzed CX best practices. Patty started her career listening to the voice of the employee, learning more about the customer elevating customer experiences. Patty serves as a senior customer experience manager at Upwork. Patty was a principal analyst – CX for eMarketer/Insider Intelligence and a patient experience consultant for Moffitt Cancer Center. She was a consultant for several years working with both small and enterprise organizations. Patty worked in retail for 27 years. She was a VP/GM for Neiman Marcus, Marshall Fields, and Lord & Taylor. Patty is a CCXP, CX-PRO and was named a CX Influencer by CX Network in 2024 and CX Scoop in 2023. She is an active member of the CXPA where she led the writing of the Book of Knowledge, launched the FL CXPA network, serves as a leader on the FL network and the Regional Council. Patty is a member of Horizon CX Board of Advisors. Resources  Upwork: https://www.upwork.com/ Please, hit the follow button and leave your feedback: Apple Podcast: https://www.cxgoalkeeper.com/apple Spotify: https://www.cxgoalkeeper.com/spotify Follow Gregorio Uglioni on Linkedin: https://www.linkedin.com/in/gregorio-uglioni/ Gregorio Uglioni is a seasoned transformation leader with over 15 years of experience shaping business and digital change, consistently delivering service excellence and measurable impact. As an Associate Partner at Forward, he is recognized for his strategic vision, operational expertise, and ability to drive sustainable growth. A respected keynote speaker and host of the well-known global podcast Business Transformation Pitch with the CX Goalkeeper, Gregorio energizes and inspires organizations worldwide with his customer-centric approach to innovation.

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Robyn Donaldson. Entrepreneur, Mentor, and Founder of Renew Construction Services & STEM Exposure

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Robyn Donaldson. Entrepreneur, Mentor, and Founder of Renew Construction Services & STEM Exposure

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Robyn Donaldson. Entrepreneur, Mentor, and Founder of Renew Construction Services & STEM Exposure